Cargando…
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease
BACKGROUND: Lipotoxicity leading to excessive caspase‐mediated apoptosis and inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan‐caspase inhibitor that decreased serum ALT and apoptotic and inflammatory markers in subjects with chronic hepatitis. AIMS: To assess whether 28 da...
Autores principales: | Shiffman, Mitchell, Freilich, Bradley, Vuppalanchi, Raj, Watt, Kymberly, Chan, Jean L., Spada, Al, Hagerty, David T., Schiff, Eugene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587784/ https://www.ncbi.nlm.nih.gov/pubmed/30430605 http://dx.doi.org/10.1111/apt.15030 |
Ejemplares similares
-
Randomised clinical trial: a leucine‐metformin‐sildenafil combination (NS‐0200) vs placebo in patients with non‐alcoholic fatty liver disease
por: Chalasani, N., et al.
Publicado: (2018) -
Randomised clinical trial: the clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China
por: Sun, J., et al.
Publicado: (2015) -
Effects of low-dose aspirin and heparin on the pregnancy outcome in women with antiphospholipid syndrome
por: Baiazid, Latifa, et al.
Publicado: (2022) -
Implementing a home-based virtual hypertension programme—a pilot feasibility study
por: Gupta, Aditi, et al.
Publicado: (2022) -
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence
por: Kruis, W., et al.
Publicado: (2017)